M. Qian - Daiichi Sankyo Inc | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 17 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Ifinatamab Deruxtecan (I-Dxd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01

C. M. Rudin,M. -J. Ahn, M. Johnson,C. L. Hann,N. Girard,M. Nishio, Y. Cheng, H. Hayashi, Y. Jung Kim,A. Navarro, Y. Chen, T. Sakai,M. Qian, J. Godard, M. Tang, J. Singh,L. Paz-Ares

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S15-S16

Cited0Views0Bibtex

Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (ifinatamab Deruxtecan) in Extensive Stage SCLC Patients

N. M. Midde, S. Hennig, B. P. Tran,M. Qian, M. Tang, J. Singh, S. S. Vaidya, Y. Lau

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S212-S212

Cited0Views0Bibtex

OA04.03 Ifinatamab Deruxtecan (I-Dxd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01

C.M. Rudin,M.-J. Ahn, M. Johnson,C.L. Hann, N. Girard,M. Nishio, Y. Cheng, H. Hayashi, Y. Jung Kim,A. Navarro, Y. Chen, T. Sakai,M. Qian, J. Godard, M. Tang, J. Singh,L. Paz-Ares

Journal of Thoracic Oncologyno. 10 (2024): S15-S16

Cited0Views0Bibtex

P1.13A.12 Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (ifinatamab Deruxtecan) in Extensive Stage SCLC Patients

N.M. Midde, S. Hennig, B.P. Tran,M. Qian, M. Tang, J. Singh, S.S. Vaidya, Y. Lau

Journal of Thoracic Oncologyno. 10 (2024): S212

Cited0Views0Bibtex

1787P Intracranial Response in Patients (pts) with Baseline (BL) Brain Metastases (BM) and Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) Treated with Ifinatamab Deruxtecan (I-Dxd) in the IDeate-Lung01 Study

M.L. Johnson,P.F. Simoes da Rocha, Y.J. Kim, Y. Chen,L.G. Paz-Ares,N. Girard,C.L. Hann,M. Nishio,M-J. Ahn,M. Qian, M. Tang, J. Godard, J. Singh,C.M. Rudin

Annals of Oncology (2024): S1062-S1063

Cited0Views0Bibtex

PS3-3 Clinical and Biomarker Data from a Phase 1/2 Trial of Ifinatamab Deruxtecan (I-Dxd; DS-7300) in Advanced Solid Tumors

T. Doi,M.R. Patel,T. Koyama,G.S. Falchook, C. Friedman,S.A. Piha-Paul,M. Gutierrez,M. Awad, A. Mattour,T. Satoh, S. Takahashi, T. Tsunoda,S. Kadowaki, Y. Watanabe,N. Okamoto, H. Goto,N. Yoshizuka,M. Qian, X. Qian, M. Johnson

Annals of Oncology (2024): S1315

Cited0Views0Bibtex

Clinical and Biomarker Data from a Phase 1/2 Trial of Ifinatamab Deruxtecan (I-Dxd; DS-7300) in Advanced Solid Tumors

T. Doi,M. R. Patel,T. Koyama,G. S. Falchook, C. Friedman,S. A. Piha-Paul,M. Gutierrez,M. Awad, A. Mattour,T. Satoh, S. Takahashi, T. Tsunoda,S. Kadowaki, Y. Watanabe,N. Okamoto, H. Goto,N. Yoshizuka,M. Qian, X. Qian, M. Johnson

ANNALS OF ONCOLOGY (2024): S1315-S1315

Cited0Views0Bibtex

610O Preliminary Results from a Phase I, First-in-human Study of DS-9606a, a Claudin 6 (Cldn6)-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) with Tumor Types Known to Express CLDN6

M.R. Patel,E.P. Hamilton,S.A. Piha-Paul, J. Henry,U. Banerji,M.N. Al Hallak, H. Okada,M. Qian, X. Zhang, N. Said,V. Chatikhine,E. Fontana

Annals of Oncology (2024): S488-S489

Cited0Views0Bibtex

Ifinatamab Deruxtecan (I-Dxd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study

M. Johnson,M. Awad,T. Koyama,M. Gutierrez,G. S. Falchook,S. A. Piha-Paul,T. Doi,T. Satoh,N. Okamoto,J. Singh,N. Yoshizuka,M. Qian, X. Qian, B. P. Tran,O. Dosunmu, R. Mucha, H. Windish,M. R. Patel

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S54-S55

Cited0Views0Bibtex

690P Ifinatamab Deruxtecan (I-Dxd; DS-7300) in Patients with Advanced Solid Tumors: Updated Clinical and Biomarker Results from a Phase I/II Study

M.R. Patel,T. Doi,T. Koyama,G.S. Falchook,C.F. Friedman,S.A. Piha-Paul,M. Gutierrez,M.M. Awad, A.H. Mattour,T. Satoh,N. Okamoto,J. Singh,N. Yoshizuka,M. Qian, X. Qian, B.P. Tran,O. Dosunmu, P. Lu,M.L. Johnson

Annals of Oncology (2023): S481-S482

Cited1Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn